» Articles » PMID: 22240894

Alternative Splicing of Bim and Erk-mediated Bim(EL) Phosphorylation Are Dispensable for Hematopoietic Homeostasis in Vivo

Overview
Specialty Cell Biology
Date 2012 Jan 14
PMID 22240894
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The pro-apoptotic BH3-only protein Bim has a major role in hematopoietic homeostasis, particularly in the lymphocyte compartment, where it strongly affects immune function. The three major Bim isoforms (Bim(EL), Bim(L) and Bim(S)) are generated by alternative splicing. Bim(EL), the most abundant isoform, contains a unique sequence that has been reported to be the target of phosphorylation by several MAP kinases. In particular, Erk1/2 has been shown to interact with Bim(EL) through the DEF2 domain of Bim(EL) and specifically phosphorylate this isoform, thereby targeting it for ubiquitination and proteasomal degradation. To examine the physiological importance of this mechanism of regulation and of the alternative splicing of Bim, we have generated several Bim knock-in mouse strains and analyzed their hematopoietic system. Although mutation in the DEF2 domain reduces Bim(EL) degradation in some circumstances, this mutation did not significantly increase Bim's pro-apoptotic activity in vivo nor impact on the homeostasis of the hematopoietic system. We also show that Bim(EL) and Bim(L) are interchangeable, and that Bim(S) is dispensable for the function of Bim. Hence, we conclude that physiological regulation of Bim relies on mechanisms independent of its alternative splicing or the Erk-dependent phosphorylation of Bim(EL).

Citing Articles

Bufotalin Induces Oxidative Stress-Mediated Apoptosis by Blocking the ITGB4/FAK/ERK Pathway in Glioblastoma.

Tan J, Lin G, Zhang R, Wen Y, Luo C, Wang R Antioxidants (Basel). 2024; 13(10).

PMID: 39456433 PMC: 11505062. DOI: 10.3390/antiox13101179.


A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling.

Lewis M, Prouzet-Mauleon V, Lichou F, Richard E, Iggo R, Turcq B Cancer Med. 2024; 9(18):6739-6751.

PMID: 38831555 PMC: 7520295. DOI: 10.1002/cam4.3231.


Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformation.

Kesarwani M, Kincaid Z, Azhar M, Azam M Blood Adv. 2024; 8(11):2765-2776.

PMID: 38531054 PMC: 11176961. DOI: 10.1182/bloodadvances.2023010830.


MAPK-negative feedback regulation confers dependence to JAK2 signaling.

Kesarwani M, Kincaid Z, Azhar M, Menke J, Schwieterman J, Ansari S Leukemia. 2023; 37(8):1686-1697.

PMID: 37430058 PMC: 10976185. DOI: 10.1038/s41375-023-01959-0.


FGF signaling regulates development by processes beyond canonical pathways.

Ray A, Mazot P, Brewer J, Catela C, Dinsmore C, Soriano P Genes Dev. 2020; 34(23-24):1735-1752.

PMID: 33184218 PMC: 7706708. DOI: 10.1101/gad.342956.120.


References
1.
Puthalakath H, OReilly L, Gunn P, Lee L, Kelly P, Huntington N . ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007; 129(7):1337-49. DOI: 10.1016/j.cell.2007.04.027. View

2.
Oliveira J, Bidere N, Niemela J, Zheng L, Sakai K, Nix C . NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 2007; 104(21):8953-8. PMC: 1885609. DOI: 10.1073/pnas.0702975104. View

3.
Cragg M, Jansen E, Cook M, Harris C, Strasser A, Scott C . Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest. 2008; 118(11):3651-9. PMC: 2571034. DOI: 10.1172/JCI35437. View

4.
Kuroda J, Puthalakath H, Cragg M, Kelly P, Bouillet P, Huang D . Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A. 2006; 103(40):14907-12. PMC: 1595449. DOI: 10.1073/pnas.0606176103. View

5.
Adams J, Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007; 26(9):1324-37. PMC: 2930981. DOI: 10.1038/sj.onc.1210220. View